Literature DB >> 3099771

Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

D C Rijken, J J Emeis.   

Abstract

In order to assess which part of the tissue-type plasminogen activator (t-PA) molecule should be (genetically) modified to obtain more-slowly-clearing mutants, two-chain t-PA and its isolated heavy and light chains were radiolabelled and injected into rats. The vast majority of t-PA and the heavy chain disappeared from the blood circulation with half-lives of 2.3 and 1.0 min respectively. The clearance of the light chain was biphasic, owing to complex-formation with plasma proteinase inhibitors. The disappearance of di-isopropylphospho-light chain, which has a blocked active site, was nearly monophasic, with a half-life of 5.7 min. Organ distribution studies showed that hepatic clearance constituted the major pathway in all cases. These results strongly suggest that t-PA is recognized by the liver primarily through the heavy chain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099771      PMCID: PMC1147186          DOI: 10.1042/bj2380643

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  16 in total

1.  Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator.

Authors:  D C Rijken; E Groeneveld
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

2.  Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.

Authors:  C Korninger; J M Stassen; D Collen
Journal:  Thromb Haemost       Date:  1981-10       Impact factor: 5.249

3.  Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.

Authors:  O Matsuo; D C Rijken; D Collen
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

4.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.

Authors:  D Pennica; W E Holmes; W J Kohr; R N Harkins; G A Vehar; C A Ward; W F Bennett; E Yelverton; P H Seeburg; H L Heyneker; D V Goeddel; D Collen
Journal:  Nature       Date:  1983-01-20       Impact factor: 49.962

5.  Purification and characterization of a melanoma cell plasminogen activator.

Authors:  P Wallén; G Pohl; N Bergsdorf; M Rånby; T Ny; H Jörnvall
Journal:  Eur J Biochem       Date:  1983-05-16

6.  Tissue plasminogen activator: chemical and physiological aspects.

Authors:  F Bachmann; I E Kruithof
Journal:  Semin Thromb Hemost       Date:  1984-01       Impact factor: 4.180

7.  In vivo metabolism of human tissue-type plasminogen activator.

Authors:  T Nilsson; P Wallén; G Mellbring
Journal:  Scand J Haematol       Date:  1984-07

8.  Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

Authors:  D C Rijken; D Collen
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

9.  Fluid endocytosis by rat liver and spleen. Experiments with 125I-labelled poly(vinylpyrrolidone) in vivo.

Authors:  J Munniksma; M Noteborn; T Kooistra; S Stienstra; J M Bouma; M Gruber; A Brouwer; D Praaning-van Dalen Dalen; D L Knook
Journal:  Biochem J       Date:  1980-11-15       Impact factor: 3.857

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  10 in total

1.  Binding of tissue plasminogen activator to human aortic endothelial cells.

Authors:  M A Sanzo; S C Howard; A J Wittwer; H M Cochrane
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

2.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 4.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

5.  39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

Authors:  M Otter; J Kuiper; R Bos; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

7.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

Authors:  G Bu; S Williams; D K Strickland; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

10.  Viral cirrhosis: an overview of haemostatic alterations and clinical consequences.

Authors:  Francesca Romana Ponziani; Valerio De Stefano; Antonio Gasbarrini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-30       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.